Patsalos P N, Elyas A A, Zakrzewska J M
University Department of Clinical Neurology, National Hospital, London, UK.
Eur J Clin Pharmacol. 1990;39(4):413-5. doi: 10.1007/BF00315422.
Oxcarbazepine, a new drug with antineuralgic properties has been evaluated in a long-term follow-up of 6 patients (2 males, 4 females; aged 42-77 years; mean 61 years), previously reported on with trigeminal neuralgia. Daily oral oxcarbazepine dose correlated significantly with both total oxcarbazepine (r = 0.851) and 10-OH-carbazepine (r = 0.958) serum concentrations. Mean percent free oxcarbazepine and 10-OH-carbazepine was 41 and 61% respectively and there was no significant difference in binding between male and female patients. Free serum concentrations of oxcarbazepine and 10-OH-carbazepine correlated significantly with total serum oxcarbazepine and 10-OH-carbazepine respectively, indicating that binding capacity of both are essentially constant within the respective ranges of 0.2-11.4 mumol.l-1 and 20-150 mumol.l-1 observed in the present study.
奥卡西平是一种具有抗神经痛特性的新药，我们对6例患者（2例男性，4例女性；年龄42 - 77岁，平均61岁）进行了长期随访评估，这些患者之前曾报道患有三叉神经痛。每日口服奥卡西平剂量与奥卡西平总血清浓度（r = 0.851）和10 - 羟基奥卡西平血清浓度（r = 0.958）均显著相关。奥卡西平游离百分比均值和10 - 羟基奥卡西平分别为41%和61%，男性和女性患者之间的蛋白结合率无显著差异。奥卡西平游离血清浓度和10 - 羟基奥卡西平分别与奥卡西平总血清浓度和10 - 羟基奥卡西平显著相关，表明在本研究观察到的各自0.2 - 11.4 μmol·L⁻¹和20 - 150 μmol·L⁻¹范围内，两者的蛋白结合能力基本恒定。
